Incredible Spirits launches spirits-based ready-to-drink shots 'SWIGGER'

Indian alco-bev start-up, Incredible Spirits (“ISPL”), has launched premium spirits-based Ready-to-Drink (RTD) shots, under the brand name SWIGGER. The premium crafted product, blended with natural and organic flavors, has been unveiled in two Gin and two Vodka variants, to begin with.

The Gin-based RTD shots have been distilled with Elderflower & Berries and Pink Grapefruit & Lime while the Vodka-based offerings have been distilled with Mandarin and Lime, Lychee and Cinnamon. The flavorful SWIGGER shots have been introduced in 60 ml double shot glasses with a pull rip cap closure, ensuring a safe and unadulterated, convenient experience for consumers.

Speaking on the launch, Arun Raina, co-founder, Incredible Spirits, said, “We are excited to launch the country’s first spirits-based Ready-to-Drink premium shots brand. The RTD shots category is a completely new segment in India and, therefore, presents an enormous opportunity.”

Recently, leading Indian-Made Foreign Liquor (IMFL) manufacturer Tilaknagar Industries, the country’s largest manufacturer of premium brandy, invested Rs 1 crore for a 19.50% equity stake in Incredible Spirits Private Limited.

With the tagline ‘Inspire fun’, the premium RTD shots brand SWIGGER has been introduced in the beach capital of India, Goa, in the first phase of its launch. This will be followed by more markets across the country.

Pranav Teredesai, co-founder, Incredible Spirits, said, “Younger consumers have become more experimental, which is giving a push to premium, on-the-go alco-bev products. SWIGGER is a first-of-its-kind offering in India’s RTD space, and through this innovation, we aim to offer a safe and enriching experience.”

This launch will be followed by the introduction of more premium shot variants with Cognac, Bourbon Whiskey, Dark Rum & Tequila.

According to the IWSR May 2022 report, the RTD market in India is a 3 million cases category in 2021, and is expected to grow at more than 9% annually over the next 5 years, reaching 4.5 million cases in 2026.